Investor Relations in a biotechnology company

Living Cell Technologies is a fast growing public bioscience company listed on the Australian Securities Exchange with over 1200 shareholders from Australasia, Europe and the United States of America. The
company is very product driven building an international entity that
will have its own capabilities of providing live cell therapies in Asia Pacific, USA and Europe.

OTCQX Listing of LCT American Depository Receipts (ADR's)

LCT has listed its American Depositary Receipts ("ADRs") on the International OTCQX and began trading Monday, June 2nd in the United States. International OTCQX provides a gateway to U.S. securities markets for international companies that are listed on a qualified international exchange and provide ongoing disclosure in English to U.S. investors. More importantly, International OTCQX distinguishes the reputable international issuers from the 8,000 over-the-counter (OTC) securities traded in the U.S. Only leading companies that have substantial operating businesses and provide credible disclosure to the public are eligible for inclusion on the premium-tier International OTCQX, which commenced trading on March 5, 2007. For more about International OTCQX, visit www.otcqx.com.

Real-time quotes for Living Cell Technologies' ADRs are available at www.otcqx.com and also available across all major U.S. quotation services and to customers of U.S. online brokers such as E*Trade, Fidelity, Scottrade, and TD Ameritrade.

U.S. investors generally find it convenient to purchase Living Cell Technologies' ADRs electronically in U.S. dollars listed on the OTCQX under the symbol LVCLY. Alternatively, ordinary shares of the company can be traded in Australian dollars on the Australian Securities Exchange under the symbol LCT. On the OTCQX Living Cell Technologies' ADRs are packaged into units, where one ADR equals ten ordinary shares.

Mailing Address

PO Box 3014
Auburn VIC 3123
Australia

Investor relations inquiries